Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na+/H+ exchange inhibitor. Sodium Channel[1]
There is no significant effects of the Na+/H+ exchange inhibitor eniporide on cardiac performance and high energy phosphate content in healthy pig hearts subjected to ischemia/reperfusion induced by crystalloid cardioplegic arrest[1].
In stage 1, the administration of 100 mg and 150 mg eniporide results in smaller infarct sizes, especially in the angioplasty group. In contrast, in stage 2 there is no difference in the enzymatic infarct size between the three groups. Overall there is no effect of eniporide on clinical outcome (death, cardiogenic shock, heart failure, life-threatening arrhythmias). However, there is a significant reduction of the incidence of heart failure in patients reperfused late (>4 h)[2].
[1]. Klass O, et al. Effect of the Na+/H+ exchange inhibitor eniporide on cardiac performance and myocardial high energy phosphates in pigs subjected to cardioplegic arrest. Ann Thorac Surg. 2004 Feb;77(2):658-63. [2]. Zeymer U, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001 Nov 15;38(6):1644-50.